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SUMMARY. In the present study matrix and multilayered matrix tablets of diltiazem HCl were formulat-
ed by using guar gum as matrix core component and cellulose derivative, Sodium Carboxy Methyl Cellu-
lose (SCMC) as barrier layers. Marked difference in dissolution characteristics of D3 and D3L3 was ob-
served and showed a statistically significant difference. The study revealed that the matrix tablets pro-
longed the release, but predominantly in a first order fashion. Layering with SCMC granules on the ma-
trix core, provided linear drug release with zero order kinetics. Mean dissolution time for D3 and D3L3
were found to be 4.17 h and 16.45 h, while dissolution efficiency decreased, indicating slower drug release.
In vivo transit time of the formulation D3L3 shows that it crossed the small intestine at 6 h and retained
for longer time in colon at 12 h. FT-IR and DSC studies show there is no drug–excipeints interaction. Sta-
bility studies portray that no change either in physical manifestation or in dissolution profile after storage
at 40 ± 2 °C/RH 75 ± 5 % for 3 and 6 months. 
